Cargando…

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience

This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast. An observational study was conducted at a single center, in the real world setting, on six persons who either switched to...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kalra, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911850/ https://www.ncbi.nlm.nih.gov/pubmed/27366727 http://dx.doi.org/10.4103/2230-8210.180644

Ejemplares similares

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2016)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
por: Mehta, Roopa, et al.
Publicado: (2020)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
por: Glastras, Sarah J., et al.
Publicado: (2020)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
por: Demir, Tevfik, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience
por: Oner, Hatice, et al.
Publicado: (2022)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
por: Kaku, Kohei, et al.
Publicado: (2017)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
por: Evans, Marc, et al.
Publicado: (2016)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Edina, Brenda C, et al.
Publicado: (2022)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series
por: Hiranput, Siwaporn, et al.
Publicado: (2018)

Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study
por: Simioni, Natalino, et al.
Publicado: (2017)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_45eu3fpmturfrqq2fupfjjt1gs